🚀 VC round data is live in beta, check it out!
PegBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for PegBio and similar public comparables like Camurus, Supernus Pharmaceuticals, Viridian Therapeutics, Almirall and more.
PegBio Overview
About PegBio
PegBio Co Ltd is engaged in the discovery and development of therapies. The company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309.
Founded
2008
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$3B
PegBio Financials
PegBio reported last fiscal year revenue of — and negative EBITDA of ($40M).
In the same fiscal year, PegBio generated ($40M) in EBITDA losses and had net loss of ($41M).
PegBio P&L
In the most recent fiscal year, PegBio reported revenue of — and EBITDA of ($40M).
PegBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($40M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($41M) | XXX | XXX | XXX |
| Net Debt | — | — | $10M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PegBio Stock Performance
PegBio has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
PegBio's stock price is $8.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPegBio Valuation Multiples
PegBio trades at (76.7x) EV/EBITDA.
PegBio Financial Valuation Multiples
As of March 7, 2026, PegBio has market cap of $3B and EV of $3B.
Equity research analysts estimate PegBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PegBio has a P/E ratio of (76.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (76.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (74.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (76.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (115.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PegBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PegBio Margins & Growth Rates
PegBio's revenue in the last fiscal year grew by —.
PegBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 2% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PegBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| Supernus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Viridian Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Almirall | XXX | XXX | XXX | XXX | XXX | XXX |
| InnoCare Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PegBio M&A Activity
PegBio acquired XXX companies to date.
Last acquisition by PegBio was on XXXXXXXX, XXXXX. PegBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PegBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPegBio Investment Activity
PegBio invested in XXX companies to date.
PegBio made its latest investment on XXXXXXXX, XXXXX. PegBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PegBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PegBio
| When was PegBio founded? | PegBio was founded in 2008. |
| Where is PegBio headquartered? | PegBio is headquartered in China. |
| Is PegBio publicly listed? | Yes, PegBio is a public company listed on HKEX. |
| What is the stock symbol of PegBio? | PegBio trades under 02565 ticker. |
| When did PegBio go public? | PegBio went public in 2025. |
| Who are competitors of PegBio? | PegBio main competitors are Camurus, Supernus Pharmaceuticals, Viridian Therapeutics, Almirall. |
| What is the current market cap of PegBio? | PegBio's current market cap is $3B. |
| Is PegBio profitable? | No, PegBio is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.